CLSA has released a research note indicating that Hansoh Pharma (03692) delivered stronger-than-expected results for the first half of the year. Revenue grew 12% year-on-year, and despite a challenging regulatory environment, reported and underlying net profit (excluding one-off gains) increased by 36% and 19% year-on-year, respectively.

Management has reaffirmed its guidance for double-digit revenue growth in 2026, which encompasses both product sales and business development income. The firm remains optimistic about the company's global expansion and the new product cycle expected post-2027.

Consequently, CLSA has raised its target price from HK$42 to HK$43.7 and reiterated an "Outperform" rating for the stock.